NanoViricides Inc (NNVC)

[arvitar]

1) NNVC has jumped on every public health scare since 2005 to pump their stock.

2) NNVC has never submitted a single IND application in spite of always "moving rapidly". Yet its major shareholder and CEO has made tens of millions of dollars via his use of NNVC funds to fund his private company.

3) According to the SEC: "Fraudsters often seek to use national crises and periods of uncertainty to lure investors into scams. "

4) NNVC has a consistent 15-yr pattern of behavior that fits the description in 3). See below.


NanoViricides Reports Initial Safety Results Regarding its Anti-Influenza and Bird Flu Drug
November, 2005
https://www.businesswire.com/news/home/20051107005498/en/NanoViricides-Reports-Initial-Safety-Results-Anti-Influenza-Bird


Novel Influenza and Bird Flu Therapeutics Moving Rapidly at NanoViricides, Inc. September, 2007
https://www.businesswire.com/news/home/20070904005487/en/Influenza-Bird-Flu-Therapeutics-Moving-Rapidly-NanoViricides


NanoViricides is on Course to Develop Bird Flu, Influenza, and Other Drugs January, 2008.
https://www.businesswire.com/news/home/20080122005644/en/NanoViricides-Develop-Bird-Flu-Influenza-Drugs


NanoViricides, Inc. Release: Anti-Dengue NanoViricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever June, 2010
https://www.biospace.com/article/releases/nanoviricides-inc-release-anti-dengue-nanoviricides-achieve-significant-protection-in-initial-in-vivo-studies-on-dengue-hemorrhagic-fever-/


NanoViricides Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency November, 2013
http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Announces%20that%20DengueCide%E2%84%A2%20Has%20Received%20Orphan%20Drug%20Designation%20From%20the%20European%20Medicines%20Agency%20(EMA).html


NanoViricides President Dr. Diwan Presented FluCide Data at the 3rd Annual Influenza Conference June, 2014
https://www.businesswire.com/news/home/20140714005478/en/NanoViricides-President-Dr.-Diwan-Presented-FluCide-Data


NanoViricides Reports That It Has Designed and Commenced Synthesis of Novel Ebola Drug Candidates September, 2014
http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Reports%20That%20It%20Has%20Designed%20and%20Commenced%20Synthesis%20of%20Novel%20Ebola%20Drug%20Candidates.html


NanoViricides Reports that Its Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model April 2015
https://www.biospace.com/article/releases/nanoviricides-inc-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model-/


NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruse June 2016
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html


NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of the Ocular Microbiology and Immunology Group (OMIG) of the American Academy of Ophthalmology October, 2017
http://www.nanoviricides.com/press%20releases/2017/NanoViricides%20to%20Present%20Results%20On%20Successful%20Treatment%20Of%20Herpes-Induced%20Acute%20Retinal%20Necrosis%20at%20the%20Annual%20Meeting.html


NanoViricides Provides Update, Says Company is Stable and is Moving Steadily towards Clinical Trials May, 2018
https://www.biospace.com/article/releases/nanoviricides-provides-update-says-company-is-stable-and-is-moving-steadily-towards-clinical-trials/?s=86
https://www.prnewswire.com/news-releases/nanoviricides-reports-on-progress-of-its-drug-candidates-against-herpesviruses-300286916.html


NanoViricides Has Initiated IND-Enabling Safety/Toxicology Studies for Its First Drug Candidate Moving towards Human Clinical Trials Feb, 2019
https://www.accesswire.com/567044/NanoViricides-Files-Quarterly-Report-for-Period-Ending-September-30-2019--HerpeCide-Drug-Candidate-IND-Enabling-Studies-Update-Progressing-Towards-Clinical-Trials


NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses. May 12, 2020
https://ih.advfn.com/stock-market/AMEX/nanoviricides-NNVC/stock-news/82433957/nanoviricides-develops-highly-effective-broad-spec